The Development and Validation of a Novel "Dual Cocktail" Probe for Cytochrome P450s and Transporter Functions to Evaluate Pharmacokinetic Drug-Drug and Herb-Drug Interactions.
cytochrome P450 (CYP)
dual cocktail
pharmacokinetic drug-drug interaction
transporter
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
30 Sep 2020
30 Sep 2020
Historique:
received:
24
08
2020
revised:
25
09
2020
accepted:
29
09
2020
entrez:
3
10
2020
pubmed:
4
10
2020
medline:
4
10
2020
Statut:
epublish
Résumé
This study was designed to develop and validate a 10 probe drug cocktail named "Dual Cocktail", composed of caffeine (Cyp1a2 in rat and CYP1A2 in human, 1 mg/kg), diclofenac (Cyp2c11 in rat and CYP2C9 in human, 2 mg/kg), omeprazole (Cyp2c11 in rat and CYP2C19 in human, 2 mg/kg), dextromethorphan (Cyp2d2 in rat and CYP2D6 in human, 10 mg/kg), nifedipine (Cyp3a1 in rat and CYP3A4 in human, 0.5 mg/kg), metformin (Oct1/2 in rat and OCT1/2 in human, 0.5 mg/kg), furosemide (Oat1/3 in rat and OAT1/3 in human, 0.1 mg/kg), valsartan (Oatp2 in rat and OATP1B1/1B3 in human, 0.2 mg/kg), digoxin (P-gp in rat and human, 2 mg/kg), and methotrexate (Mrp2 in rat and MRP2 in human, 0.5 mg/kg), for the evaluation of pharmacokinetic drug-drug and herb-drug interactions through the modulation of a representative panel of CYP enzymes or transporters in rats. To ensure no interaction among the ten probe substrates, we developed a 2-step evaluation protocol. In the first step, the pharmacokinetic properties of five individual CYP probe substrates and five individual transporter substrates were compared with the pharmacokinetics of five CYP cocktail or five transporters cocktails in two groups of randomly assigned rats. Next, a pharmacokinetic comparison was conducted between the CYP or transporter cocktail group and the dual cocktail group, respectively. None of the ten comparison groups was found to be statistically significant, indicating the CYP and transporter substrate sets or dual cocktail set could be concomitantly administered in rats. The "Dual Cocktail" was further validated by assessing the metabolism of nifedipine and omeprazole, which was significantly reduced by a single oral dose of ketoconazole (10 mg/kg); however, no changes were observed in the pharmacokinetic parameters of other probe substrates. Additionally, multiple oral doses of rifampin (20 mg/kg) reduced the plasma concentrations of nifedipine and digoxin, although not any of the other substrates. In conclusion, the dual cocktail can be used to characterize potential pharmacokinetic drug-drug interactions by simultaneously monitoring the activity of multiple CYP isoforms and transporters.
Identifiants
pubmed: 33007943
pii: pharmaceutics12100938
doi: 10.3390/pharmaceutics12100938
pmc: PMC7600799
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : MAFRA and MSIT
ID : MAFRA (No 316017-3), MSIT (No. NRF-2020R1A5A2017323 and NRF-2020R1I1A3074384)
Références
Cancer Res. 1997 Aug 15;57(16):3506-10
pubmed: 9270020
Clin Pharmacokinet. 2016 Jan;55(1):79-91
pubmed: 26123704
Molecules. 2020 Jan 31;25(3):
pubmed: 32023909
Xenobiotica. 2007 May;37(5):459-73
pubmed: 17523050
Drug Metab Dispos. 2014 Jun;42(6):1067-73
pubmed: 24671957
Exp Toxicol Pathol. 1999 Jul;51(4-5):369-74
pubmed: 10445400
Drug Metab Dispos. 2014 Mar;42(3):301-17
pubmed: 24335390
Molecules. 2019 Aug 19;24(16):
pubmed: 31430908
J Clin Invest. 2007 May;117(5):1422-31
pubmed: 17476361
Drug Metab Dispos. 2015 Nov;43(11):1823-37
pubmed: 26296709
J Clin Pharmacol. 2012 Jun;52(6):932-9
pubmed: 21646440
Expert Opin Drug Metab Toxicol. 2013 Mar;9(3):237-52
pubmed: 23256482
BMC Complement Altern Med. 2014 Jul 17;14:251
pubmed: 25034211
Pharmacol Toxicol. 1999 Oct;85(4):157-61
pubmed: 10563513
Biopharm Drug Dispos. 2014 May;35(4):228-36
pubmed: 24395703
Altern Med Rev. 1998 Jun;3(3):187-98
pubmed: 9630736
Clin Ther. 2018 Aug;40(8):1322-1337
pubmed: 30078466
J Antimicrob Chemother. 2003 Feb;51(2):453-7
pubmed: 12562722
Expert Opin Drug Metab Toxicol. 2006 Dec;2(6):875-94
pubmed: 17125407
J Clin Invest. 1999 Jul;104(2):147-53
pubmed: 10411543
Xenobiotica. 2012 May;42(5):483-95
pubmed: 22416982
J Ginseng Res. 2016 Oct;40(4):375-381
pubmed: 27746690
Biopharm Drug Dispos. 2008 Sep;29(6):311-23
pubmed: 18651556
Molecules. 2018 Nov 12;23(11):
pubmed: 30424502
Nat Rev Drug Discov. 2010 Mar;9(3):215-36
pubmed: 20190787
Clin Pharmacokinet. 2019 Jul;58(7):911-926
pubmed: 30675694
Bioanalysis. 2014 Jan;6(1):13-9
pubmed: 24256335
Pharmaceutics. 2019 Apr 18;11(4):
pubmed: 31003498
J Ethnopharmacol. 2012 Nov 21;144(2):225-33
pubmed: 22925946
J Pharmacokinet Pharmacodyn. 2009 Dec;36(6):585-611
pubmed: 19936896
Sci Rep. 2017 Jul 19;7(1):5813
pubmed: 28725042
Drug Metab Pharmacokinet. 2018 Feb;33(1):90-95
pubmed: 29338933
Pharm Res. 2003 Jan;20(1):31-7
pubmed: 12608533
J Ginseng Res. 2014 Jul;38(3):161-6
pubmed: 25378989
Diabetes Care. 1995 Oct;18(10):1373-5
pubmed: 8721940
Rapid Commun Mass Spectrom. 2010 Aug 30;24(16):2407-19
pubmed: 20658680
Int J Oncol. 2015;46(6):2670-8
pubmed: 25892545
Gastroenterol Jpn. 1987 Aug;22(4):413-8
pubmed: 3666382
J Pharm Sci. 2006 Nov;95(11):2543-52
pubmed: 16937336
Drug Metab Pharmacokinet. 2005 Jun;20(3):177-82
pubmed: 15988119
Drug Des Devel Ther. 2015 May 22;9:2745-56
pubmed: 26045660
Mediators Inflamm. 2014;2014:748964
pubmed: 24833816
Drug Metab Dispos. 2008 Feb;36(2):268-75
pubmed: 17962372
Front Pharmacol. 2020 May 28;11:802
pubmed: 32547398
J Pharm Pharmacol. 2000 Nov;52(11):1337-43
pubmed: 11186241
Drugs Aging. 2005;22(6):525-39
pubmed: 15974642
Pharmaceutics. 2018 Jul 03;10(3):
pubmed: 29970815
Pharmaceutics. 2018 Jul 02;10(3):
pubmed: 30004443
Drug Metab Dispos. 1987 Nov-Dec;15(6):735-9
pubmed: 2893696
Pharmacoepidemiol Drug Saf. 2018 Aug;27(8):885-893
pubmed: 29797447
J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Jul 15;1026:236-253
pubmed: 26675080
Clin Pharmacol Ther. 2009 Jan;85(1):78-85
pubmed: 18843263
Xenobiotica. 2012 Apr;42(4):349-54
pubmed: 22321050
Int J Legal Med. 2008 Mar;122(2):109-14
pubmed: 17569072
Drug Discov Ther. 2015 Feb;9(1):23-32
pubmed: 25788049
Clin Pharmacol Ther. 2014 Sep;96(3):349-59
pubmed: 24722393
Drug Metab Pharmacokinet. 2008;23(4):243-53
pubmed: 18762711
Clin Pharmacol Ther. 2002 Sep;72(3):276-87
pubmed: 12235448
Evid Based Complement Alternat Med. 2013;2013:593181
pubmed: 24319479
Eur J Drug Metab Pharmacokinet. 2016 Jun;41(3):231-8
pubmed: 25549928
Arch Pharm Res. 2019 Oct;42(10):862-878
pubmed: 31493264
Eur J Clin Pharmacol. 1998 Apr;54(2):159-61
pubmed: 9626921
Drug Metab Dispos. 2006 Jul;34(7):1247-54
pubmed: 16624871
Evid Based Complement Alternat Med. 2014;2014:168940
pubmed: 24876866
Adv Clin Exp Med. 2016 Mar-Apr;25(2):237-42
pubmed: 27627555
Drug Metab Dispos. 2019 May;47(5):493-503
pubmed: 30862625
Arch Pharm Res. 2005 Oct;28(10):1196-202
pubmed: 16276979
Bioanalysis. 2018 Sep 1;10(17):1401-1411
pubmed: 30182747
J Clin Diagn Res. 2014 Nov;8(11):HC01-4
pubmed: 25584241
Clin Pharmacol Ther. 2007 Nov;82(5):531-40
pubmed: 17392720
J Clin Pharmacol. 2011 Jan;51(1):75-83
pubmed: 20702754
J Pharm Sci. 2006 Sep;95(9):1984-93
pubmed: 16850393